Tag: pharmaceuticals

  • FDA Issues Draft Guidance on Diagnostic/Therapy Companions

    The U.S. Food and Drug Administration (FDA) issued a draft of guidance to encourage the development and review of diagnostics tests to help health care professionals determine if a patient should receive a particular drug therapy or its dosage. The agency is seeking public input on the draft guidance for 60 days. The draft document…

  • Company-Institute Teams to Tackle Residual HIV Infection

    The National Institute of Allergy and Infectious Diseases (NIAID) of National Institutes of Health awarded three research teams more than $14 million a year, for up to five years, to develop strategies to help rid the body of HIV infections. The grants to project teams composed of private companies and universities or research institutes are…

  • Adult Stem Cells Help Cardiac Function in Angina Patients

    A clinical trial by researchers at Baxter International in Deerfield, Illinois and Northwestern University medical school in Chicago found injections of individuals’ own stem cells reduced angina episodes and improved exercise tolerance time in patients with chronic, severe angina who did not respond to other treatments. The results of the research appear online in the…

  • Generic Drugs Can Generate Sharp Health Care Cost Reductions

    Researchers from Harvard University, Brigham and Women’s Hospital in Boston, and CVS Caremark have found that expanded use of generic medications for chronic disease can significantly reduce the cost of preventive health care. Their findings appear in the July issue of the journal Health Affairs (paid subscription required). The study concludes that preventive health care…

  • Sanofi, Rib-X to Collaborate on New Types of Antibiotics

    The global pharmaceutical firm Sanofi has agreed to jointly develop new antibiotic technology with the biotechnology company Rib-X Pharmaceuticals in New Haven, Connecticut. The agreement includes an option for Sanofi to license the technology from Rib-X that treats resistant pathogens. Rib-X’s RX-04 program is developing new types of antibiotics aimed at drug-resistant pathogens, which the…

  • Trial Shows Drug Combo Extends Time Without Tumor Growth

    The global pharmaceutical company Novartis says its drug everolimus, when used in combination with exemestane, extended the time without tumor growth, when compared to placebo plus exemestane, in women with advanced breast cancer. The study included postmenopausal women with metastatic breast cancer whose disease has progressed, despite initial endocrine therapy. Novartis says the clinical trial…

  • Pharmas, BioPontis Alliance Partner on Translational Science

    BioPontis Alliance, a hybrid investment fund and product development company in Raleigh, North Carolina, and global pharmaceutical company Pfizer Inc. agreed to collaborate on translational technology development supported by BioPontis. The companies announced the deal at the 2011 BIO International Convention in Washington, D.C. BioPontis establishes research alliances with academic-research institutes, where BioPontis searches for…

  • Computerized Outpatient Prescriptions Still Have Errors

    Researchers from three Boston, Massachusetts medical centers, Harvard Medical School, and CVS Pharmacies analyzed records from automated prescription systems and found error rates similar to prescriptions written manually. The team’s findings appear online in the Journal of the American Medical Informatics Association (paid subscription required). The panel of clinicians reviewed 3,850 prescription records from a…

  • Biotech, NGO Partnership Advances Sleeping Sickness Drug

    A consortium of two biotechnology companies and non-government organization have completed preclinical studies of a potential treatment for sleeping sickness. The partners — Anacor Pharmaceuticals in Palo Alto, California, SCYNEXIS Inc. in Research Triangle Park, North Carolina, and Drugs for Neglected Diseases initiative (DNDi) in Geneva, Switzerland — published their findings in the journal PLoS…

  • BARDA Gets SIGA Smallpox Antiviral Drug, Protest Withdrawn

    SIGA Technologies Inc. in New York says the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. Department of Health and Human Services will acquire 1.7 million courses of SIGA’s smallpox antiviral drug ST-246. SIGA competitor Chimerix Inc. of Durham, North Carolina dropped its protest of Barda’s sole-source contract award in May to SIGA.…